ArticleFrontiers in pharmacology2026
Exercise-induced myokine irisin protects against obesity-associated ischemic stroke via integrin αVβ5 signaling.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke in the context of obesity represents a growing clinical challenge, yet obesity-specific neuroprotective strategies remain largely unexplored. Here, we investigated whether exercise-induced irisin, a myokine generated by proteolytic cleavage of fibronectin type III domain-containing protein 5 (FNDC5) in skeletal muscle, confers neuroprotection in a high-fat diet (HFD)-induced obese mouse model of transient middle cerebral artery occlusion (MCAO). Treadmill exercise reduced infarct size and restored circulating and cerebral FNDC5/irisin levels that were suppressed by obesity and ischemic injury. Intraperitoneal administration of recombinant irisin recapitulated these protective effects, reducing infarct volume and neurological deficits while upregulating the tight junction proteins occludin and claudin-5, suppressing microglial activation, promoting M2 macrophage polarization, and inhibiting NLRP3 inflammasome-mediated pyroptosis, as evidenced by reductions in cleaved caspase-1 and gasdermin D protein. Irisin treatment also significantly increased the protein expression of its receptor, integrin αVβ5. Conversely, genetic deletion of FNDC5 exacerbated ischemic outcomes, disrupted blood-brain barrier integrity, aggravated neuroinflammation, and reduced integrin αVβ5 expression, collectively mirroring the pathological features reversed by exogenous irisin. Pharmacological blockade of integrin αVβ5 with cilengitide abolished the neuroprotective effects of irisin, establishing the receptor-dependent nature of its actions. These findings demonstrate that the FNDC5/irisin/integrin αVβ5 axis functions as a receptor-dependent, exercise-inducible neuroprotective pathway in obesity-associated ischemic stroke, and identify recombinant irisin as a promising ""exercise mimetic"" with therapeutic potential for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.